secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-09-11T20:05:52+00:00
Accession:  0001193125-26-389264
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva prices $4.9B senior notes to refinance higher-coupon debt
--------------------------------------------------------------

- EUR tranches: €1.0B 4.250% due 2033, €500M 4.625% due 2036.
- USD tranches: $1.0B 5.500% due 2034, $1.0B 5.750% due 2037, $1.2B 5.250% due 2032.
- Closing expected Sept 16, 2026; senior unsecured, guaranteed by Teva.
- Proceeds fund redemptions: all 6.750% 2028, 7.875% 2029, 7.375% 2029, up to $450M 4.750% 2027, €1.25B 4.375% 2030 (reduced to €1.15B).
- Also plans to redeem all 8.125% 2031 notes; remainder for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/0001193125-26-389264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer